This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Fabio Capuano Antonino Roscitano Umberto Benedetto Riccardo Sinatra Permission Requests Google Scholar Articles by Capuano, F. Articles by Sinatra, R. PubMed PubMed Citation Articles by Capuano, F. Articles by Sinatra, R. Related Collections Coronary disease Extracorporeal circulation

Neutrophil gelatinase-associated lipocalin levels after use of mini-cardiopulmonary bypass system

^a Department of Cardiac Surgery, II Faculty of Medicine, University La Sapienza, Sant' Andrea Hospital, Rome, Italy
^b Department of Nefrology, II Faculty of Medicine, University La Sapienza, Sant' Andrea Hospital, Rome, Italy
^c Department of Biochemical Sciences and Laboratory of Advanced Molecular Diagnostics, II Faculty of Medicine, University La Sapienza, Sant' Andrea Hospital, Rome, Italy

*Corresponding author. Sant' Andrea Hospital, University of Rome ‘La Sapienza’, Via di Grottarossa 1035, 00189 Rome, Italy. Tel.: +390633775310; fax: +390633775483.

E-mail address: capmd{at}katamail.com (F. Capuano).

Neutrophil gelatinase-associated lipocalin (NGAL) has been implicated as an early predictive urinary biomarker of ischemic acute kidney injury (AKI). The aim of this study was to compare the effects of miniaturized cardiopulmonary bypass system (MCPB) vs. standard cardiopulmonary bypass system (SCPB) system on kidney tissue in patients undergoing myocardial revascularization using urinary NGAL levels as an early marker for renal injury. Sixty consecutive patients who underwent myocardial revascularization were studied prospectively. An SCPB was used in 30 patients (group A) and MCPB was used in 30 patients (group B). The SCPB group but not the MCPB group showed a significant NGAL concentration increase from preoperative during the 1st postoperative day (169.0±163.6 ng/ml in the SCPB group vs. 94.1±99.4 ng/ml in the MCPB group, P<0.05, respectively). Two patients in the SCPB group developed AKI and underwent renal replacement therapy; no patient in MCPB developed AKI. The MCPB system is safe in routine clinical use. Kidney function is better protected during MCPB as demonstrated by NGAL levels. NGAL represents an early biomarker of renal failure in patients undergoing cardiac surgery and the valuation of its concentration can aid in medical decision-making.

Key Words: Coronary artery bypass grafts (CABG); Cardiopulmonary bypass (CPB); Kidney